AnalystBook Research · Company Intelligence

BIO KEY INTERNATIONAL INC

BKYI

Built from BIO KEY INTERNATIONAL INC's own SEC filings · updates as new filings land · every figure links to its source

or browse all covered companies

BIO-key narrowed losses and drew insider purchases, but the FY2024 cash-flow deficit and going-concern risk remain central.

The read at a glance✓ Verified against SEC data
  • Business mixIdentity and biometricsNote
  • Gross profitGross profit rose to $5.6MOK
  • LossNet loss narrowed 49.5%OK
  • Cash flowOCF still -$2.9MWatch
  • DebtDebt down 76.3%OK
  • Insiders3 purchases / 0 salesOK
  • AccountingForensic screens unavailableNote

Business

BIO-key sells identity and access management software, biometric technology, cloud identity services, and authentication hardware.

Where the revenue comes from

Fiscal 2025, as BIO KEY INTERNATIONAL INC reports it. History and quarterly detail are in the app.

  • License$3.4M
  • Hardware$1.3M
  • Service$1.2M

Leadership changes

From BIO KEY INTERNATIONAL INC's own filings, the day they're filed.

  • Thomas E. Bush III · departureeff. 2023-11-08

Latest filings

  • 8-K · Company announcement2026-07-09
  • 8-K · Company announcement2026-07-07
  • 10-Q · Quarterly report2026-06-22
  • 10-K · Annual report2026-06-12
  • 8-K · Company announcement2026-06-10
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, every figure source-linked🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask anything about BIO KEY INTERNATIONAL INC, every answer cited🔒

Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.